Vascular endothelial growth factor-B and DNA coding therefor

Abstract

VEGF-B polypeptides from the PDGF family of growth factors having the property of promoting mitosis and proliferation of vascular endothelial cells, DNA sequences encoding these polypeptides, pharmaceutical compositions containing them and antibodies which react with them. The VEGF-B polypeptides are useful in stimulating angiogenesis as well as in diagnostic applications.

Description

BACKGROUND OF THE INVENTION

Angiogenesis, or the proliferation of new capillary blood vessels, is a fundamental process necessary for normal growth and development of tissues. It is a prerequisite for the development and differentiation of the vascular tree, as well as for a wide variety of fundamental physiological processes including embryogenesis, somatic growth, tissue and organ repair and regeneration, cyclical growth of the corpus luteum and endometrium, and development and differentiation of the nervous system. In the female reproductive system, angiogenesis occurs in the follicle during its development, in the corpus luteum following ovulation and in the placenta to establish and maintain pregnancy. Angiogenesis additionally occurs as part of the body's repair processes, e.g. in the healing of wounds and fractures. Angiogenesis is also a factor in tumor growth, since a tumor must continuously stimulate growth of new capillary blood vessels in order to grow.

Capillary blood vessels consist of endothelial cells and pericytes. These two cell types carry all of the genetic information to form tubes, branches and entire capillary networks. Specific angiogenic molecules can initiate this process. In view of the physiological importance of angiogenesis, much effort has been devoted to the isolation, characterization and purification of factors that can stimulate angiogenesis, and a number of polypeptides which stimulate angiogenesis have been purified and characterized as to their molecular, biochemical and biological properties. For reviews of such angiogenesis regulators, see Klagsbrun et al., "Regulators of Angiogenesis", Ann. Rev. Physiol., 53:217-39 (1991); and Folkman et al., "Angiogenesis," J. Biol. Chem., 267:10931-934 (1992).

One such growth factor, which is highly specific as a mitogen for vascular endothelial cells, is termed vascular endothelial growth factor (VEGF). See Ferrara et al., "The Vascular Endothelial Growth Factor Family of Polypeptides," J. Cellular Biochem., 47:211-218 (1991); Connolly, "Vascular Permeability Factor: A Unique Regulator of Blood Vessel Function," J. Cellular Biochem., 47:219-223 (1991). VEGF is a potent vasoactive protein that has been detected in media conditioned by a number of cell lines including bovine pituitary follicular cells. VEGF is a glycosylated cationic 46-48 kD dimer made up of two 24 kD subunits. It is inactivated by sulfhydryl reducing agents, resistant to acidic pH and to heating, and binds to immobilized heparin. VEGF is sometimes referred to as vascular permeability factor (VPF) because it increases fluid leakage from blood vessels following intradermal injection. It also has been called by the name vasculotropin.

Four different molecular species of VEGF have been detected. The 165 amino acid species has a molecular weight of approximately 46 kD and is the predominant molecular form found in normal cells and tissues. A less abundant, shorter form with a deletion of 44 amino acids between positions 116 and 159 (VEGF.sub.121), a longer form with an insertion of 24 highly basic residues in position 116 (VEGF.sub.189), and another longer form with an insertion of 41 amino acids (VEGF.sub.206), which includes the 24 amino acid insertion found in VEGF.sub.189, are also known. VEGF.sub.121 and VEGF.sub.165 are soluble proteins. VEGF.sub.189 and VEGF.sub.206 appear to be mostly cell-associated. All of the versions of VGEF are biologically active. For example, each of the species when applied intradermally is able to induce extravasation of Evans blue.

The various species of VEGF are encoded by the same gene and arise from alternative splicing of messenger RNA. This conclusion is supported by Southern blot analysis of human genomic DNA, which shows that the restriction pattern is identical using either a probe for VEGF.sub.165 or one which contains the insertion in VEGF.sub.206. Analysis of genomic clones in the area of putative mRNA splicing also shows an intron/exon structure consistent with alternative splicing.

Analysis of the nucleotide sequence of the VEGF gene indicates that VEGF is a member of the platelet-derived growth factor (PDGF) family. The amino acid sequence of VEGF exhibits approximately 20% homology to the sequences of the A and B chains of PDGF, as well as complete conservation of the eight cysteine residues found in both mature PDGF chains. VEGF.sub.165, VEGF.sub.189 and VEGF.sub.206 also contain eight additional cysteine residues within the carboxy-terminal region. The amino-terminal sequence of VEGF is preceded by 26 amino acids corresponding to a typical signal sequence. The mature protein is generated directly following signal sequence cleavage without any intervening prosequence. The existence of a potential glycosylation site at Asn.sup.74 is consistent with other evidence that VEGF is a glycoprotein, but the polypeptide has been reported to exist in both glycosylated and deglycosylated species.

Like other cytokines, VEGF can have diverse effects that depend on the specific biological context in which it is found. VEGF is a potent endothelial cell mitogen and directly contributes to induction of angiogenesis in vivo by promoting endothelial cell growth during normal development or during wound healing. A most striking property of VEGF is its specificity. It is mitogenic in vitro at 1 ng/ml for capillary and human umbilical vein endothelial cells, but not for adrenal cortex cells, corneal or lens epithelial cells, vascular smooth muscle cells, corneal endothelial cells, granulosa cells, keratinocytes, BHK-21 fibroblasts, 3T3 cells, rat embryo fibroblasts, human placental fibroblasts and human sarcoma cells. The target cell specificity of VEGF is thus restricted to vascular endothelial cells. VEGF can trigger the entire sequence of events leading to angiogenesis and stimulates angiogenesis in vivo in the cornea and in a healing bone graft model. It is able to stimulate the proliferation of endothelial cells isolated from both small and large vessels. Expression of VEGF mRNA is temporally and spatially related to the physiological proliferation of capillary blood vessels in the ovarian corpus luteum or in the developing brain. VEGF expression is triggered by hypoxemia so that endothelial cell proliferation and angiogenesis appear to be especially stimulated in ischemic areas. VEGF is also a potent chemoattractant for monocytes. In addition, VEGF induces plasminogen activator and plasminogen activator inhibitor in endothelial cells.

Tumor cells release angiogenic molecules such as VEGF, and monoclonal antibodies to VEGF have been shown to inhibit the growth of certain types of tumor such as rhabdomyosarcoma. See Kim et al., "Inhibition of Vascular Endothelial Growth Factor-Induced Angiogenesis Suppresses Tumor Growth in vivo," Nature, 362:841-844 (1993). This suggests that blocking VEGF action is of potential therapeutic significance in treating tumors in general, and highly-vascularized, aggressive tumors in particular.

SUMMARY OF THE INVENTION

It is an object of the invention to provide a new growth factor having the property of promoting proliferation of endothelial cells.

Another object of the invention is to provide isolated DNA sequences which encode a new growth factor which promotes proliferation of endothelial cells.

It is also an object of the invention to provide new products which may be useful in diagnostic and/or therapeutic applications.

These and other objects are achieved in accordance with the present invention by providing an isolated DNA which codes for a protein having the property of promoting proliferation of endothelial cells or mesodermal cells, the DNA being selected from the group consisting of the DNA of FIGS. 1 and 2 (SEQ ID NO:1), the DNA of FIG. 3 (SEQ ID NO:4), the DNA of FIG. 5 (SEQ ID NO:6); the DNA of FIG. 7 (SEQ ID NO:8), and DNA's which hybridize under stringent conditions with at least one of the foregoing DNA sequences.

In accordance with further aspects of the invention, the objects are also achieved by providing a protein having the property of promoting proliferation of endothelial cells or mesodermal cells, which protein comprises a sequence of amino acids substantially corresponding to an amino acid sequence selected from the group consisting of the amino acid sequence of FIG. 1 (SEQ ID NO:2), the amino acid sequence of FIG. 2 (SEQ ID NO:3), the amino acid sequence of FIG. 4 (SEQ ID NO:5), the amino acid sequence of FIG. 6 (SEQ ID NO:7), and the amino acid sequence of FIG. 8 (SEQ ID NO:9); and by providing pharmaceutical preparations which comprise such proteins; and by providing antibodies which react with such proteins.

Clinical applications of the invention include diagnostic applications, acceleration of angiogenesis in wound healing, and inhibition of angiogenesis. Quantitation of VEGF-B in cancer biopsy specimens may be useful as an indicator of future metastatic risk. Topical application of VEGF-B preparations to chronic wounds may accelerate angiogenesis and wound healing.

BRIEF DESCRIPTION OF THE DRAWINGS

FIG. 1 shows the nucleotide sequence of the (partial) cDNA clone of VEGF-B (SEQ ID NO: 1) and the amino acid sequence of the protein segment (SEQ ID NO:2) coded by the first reading frame of the cDNA;

FIG. 2 repeats the nucleotide sequence of the (partial) cDNA clone of VEGF-B (SEQ ID NO:1) and the amino acid sequence of the protein segment (SEQ ID NO:3) coded by the second reading frame of the cDNA;

FIG. 3 shows the nucleotide sequence of the coding region of a full length cDNA clone of VEGF-B.sub.166 (SEQ ID NO:4);

FIG. 4 shows the amino acid sequence of VEGF-B.sub.166 (SEQ ID NO:5);

FIG. 5 shows the nucleotide sequence of the coding region of a cDNA clone of VEGF-B.sub.173 (SEQ ID NO:6);

FIG. 6 shows the amino acid sequence of VEGF-B.sub.173 (SEQ ID NO:7);

FIG. 7 shows the nucleotide sequence of a cDNA clone of VEGF-B.sub.112 (SEQ ID NO: 8);

FIG. 8 shows the amino acid sequence of VEGF-B.sub.112 (SEQ ID NO:9);

FIG. 9 shows a comparison of the amino acid sequences of PDGF-A (SEQ ID NO:12) PDGF-B (SEQ IN NO:13) PlGF (SEQ ID NO:14) VEGF (SEQ ID NO:15) and VEGF-B (SEQ ID NO:5).

FIG. 10 shows the nucleotide sequence of a clone of human VEGF-B.sub.166 (SEQ ID NO: 10 );

FIG. 11 shows the amino acid sequence of human VEGF-B.sub.166 (SEQ ID NO:11); and

FIG. 12 shows a comparison of the sequences of murine (SEQ ID NO: 5) and human (SEQ ID NO:11) VEGF-B.sub.166.

DETAILED DESCRIPTION OF PREFERRED EMBODIMENTS

The present invention thus is directed to new vascular endothelial growth factors, hereinafter referred to as VEGF-B growth factors, which share the angiogenic and other properties of VEGF, but which are distributed and expressed in tissues differently from VEGF.

VEGF-B growth factors are members of the family of platelet derived growth factors and are a growth factors which promote mitosis and proliferation of vascular endothelial cells and/or mesodermal cells. They are produced by expression of DNA sequences which correspond to, or which are hybridizable under stringent conditions with, any one of the DNA sequences depicted in FIGS. 1 and 2 (SEQ ID NO:1), FIG. 3 (SEQ ID NO:4), FIG. 5 (SEQ ID NO:6) or FIG. 7 (SEQ ID NO:8). It is intended to include within the scope of the invention all angiogenic proteins encoded by DNA sequences which hybridize under stringent conditions to any one of the foregoing DNA sequences. Suitable hybridization conditions include, for example, 50% formamide, 5.times. SSPE buffer, 5.times. Denhardts solution, 0.5% SDS and 100 .mu.g/ml of salmon sperm DNA at 42.degree. C. overnight, followed by washing 2.times.30 minutes in 2.times. SSC at 55.degree. C.

The invention is also directed to an isolated and/or purified DNA which corresponds to, or which hybridizes under stringent conditions with, any one of the foregoing DNA sequences.

In a further aspect, the invention is directed to antibodies of VEGF-B growth factors, and particularly to monoclonal antibodies.

VEGF-B proteins are believed to interact with protein tyrosine kinase growth factor receptors. Details of such receptors are known in the art [See e.g. Wilks, A. F., "Protein Tyrosine Kinase Growth Factor Receptors and Their Ligands in Development, Differentiation, and Cancer," Adv. Cancer Res., 60:43-73 (1993)].

Various adult mouse tissues were tested for expression of transcripts corresponding to VEGF-B by Northern blotting. The size of the mRNA was 1.3-1.4 kb. A mouse multiple tissue Northern blot (MTN, Clontech) was probed with the 0.89 kb Sal1-Not1 fragment derived from the pPC67 yeast expression vectors described above. The probe was labelled with .sup.32 P-dCTP using random priming (specific activity 10.sup.8 -10.sup.9 cpm/.mu.g of DNA). The blot was hybridized overnight at 42.degree. C. using 50% formamide, 5.times. SSPE buffer, 2% SDS, 10.times. Denhardts solution, 100 .mu.g/ml salmon sperm DNA and 1.times.10.sup.6 cpm of the labelled probe/ml. The blot was washed at room temperature for 2.times.30 min in 2.times. SSC containing 0.05% SDS and then for 2.times.20 min at 52.degree. C. in 0.1.times. SSC containing 0.1% SDS. The blot was then exposed at -70.degree. C. for three days using intensifying screens. Kodak XAR film was used. The relative expression levels as determined by visual examinations of the film are listed in the following table:

TABLE 1______________________________________Distribution of VEGF-B Transcripts in the Adult MouseTissue Relative Expression Level______________________________________Heart +++++Brain +++Spleen (+)Lung ++Liver +Skeletal Muscle ++++Kidney +++Testis (+)______________________________________ +++++ = very strong expression; ++++ = strong expression; +++ = moderate expression; ++ = rather weak expression; + = weak expression; (+) = very weak expression.

A human multiple tissue Northern blot (MNT) from Clontech was probed using the murine partial cDNA to determine relative VEGF-B expression levels in various human tissues. The size of the transcript was 1.3-1.4 kb. The conditions were identical to those used for the mouse Northern blot described above. The relative VEGF-B transcript levels for the human Northern blot are listed in the following Table 2. For comparison purposes, Table 2 also lists relative expression level data from the literature for VEGF in various mammalian systems.

TABLE 2______________________________________ Relative Expression Levels VEGF-B VEGF (Northern (from literature) blot) guineaTissues human human murine pig______________________________________heart +++++ ++ +++ +++brain + + +placenta +lung + ++++ ++liver (+) ++ (+) +skeletal ++++ +++ +musclekidney + ++ + ++pancreas +++spleen ++ - +thymus + -prostate +++testis ++ (+)ovary +++ -small ++intestinecolon +++peripheral +bloodleucocytes______________________________________

From a comparison of Table 1 and Table 2 it can be seen that mouse and human tissue expression levels of VEGF-B transcripts are relatively similar with the highest expression levels being found in heart and skeletal muscle. Significant differences may be seen in brain and kidney tissue. It should also be noted that tissues containing a large proportion of epithelial cells, such as prostate, pancreas and colon from which some of the most common human tumors originate, express relatively high levels of VEGF-B.

A comparison of the relative expression levels of VEGF and VEGF-B in human tissues shows some striking differences. VEGF is expressed rather weakly by human heart tissue, but VEGF-B is very strongly expressed by the same tissue. On the other hand, VEGF is strongly expressed by human lung tissue, but VEGF-B is only weakly expressed by human lung tissue. In a similar vein, human liver tissue expresses VEGF at a moderate level, but VEGF-B is expressed only very weakly. These data evidence that despite their general similarities, the actions of VEGF and VEGF-B are not completely identical.

EXAMPLE 1

Partial cDNA clone with two reading frames.

A partial cDNA clone encoding murine VEGF-B was identified as follows. A cDNA library (E 14.5) derived from poly A+ mRNA isolated from 14.5 day old mouse embryos [Chevray P. and Nathans D., "Protein interaction cloning in yeast: Identification of mammalian proteins that react with the leucine zipper of Jun, " Proc. Natl. Acad. Sci. USA, 89:5789-93 (1992)] was screened for cellular proteins which potentially might interact with cellular retinoic acid-binding protein type 1 (CRABP-I) using a yeast two-hybrid interaction trap screening technique as described by Gyuris J., Golemis E., Chertkov H. and Brent R., "Cdil, a Human G1 and S Phase Protein Phosphatase That Associates with Cdk2, " Cell, 75:791-803 (1993). This screening technique involves a fusion protein that contains a binding domain and that is known to be transcriptionally inert (the "bait"); reporter genes that have no basal transcription and that are bound by the bait; and an expression library which encodes proteins expressed as chimeras and whose amino termini contain an activation domain and other useful moieties (the "prey"). The screened library was a plasmid library in the yeast expression vector pPC67 obtained from Dr. Pierre Chevray of the Johns Hopkins University, School of Medicine, 725 North Wolfe St., Baltimore, Md. 21205. A positive cDNA clone (pcif-2) was recovered from the screening. The positive clone was sequenced using well known, conventional techniques and found to encode a protein highly homologous to VEGF and the other members of the PDGF family of growth factors. The 890 base pair SalI-NotI insert in the plasmid pPC67 was cloned into pBluescript and fully sequenced using T7 and T3 vector primers together with internal primers. The plasmid pBluescript is commercially available from Stratagene Inc., LaJolla, Calif. The cDNA insert was found to be 886 base pairs long and to encode two polypeptides in different reading frames which were homologous to the N-terminal end and the C-terminal end, respectively, of VEGF. This novel growth factor is referred to hereinafter as VEGF-B. The clone is partial and lacks several amino acids in the amino terminal region and the entire signal sequence.

FIG. 1 shows the nucleotide sequence (SEQ ID NO:1) of this partial cDNA clone of VEGF-B and the amino acid sequence (SEQ ID NO:2) encoded in the first reading frame thereof. The DNA sequence of FIG. 1 was obtained by conventional sequencing of a clone (pcif-2) in the yeast expression vector pPC67. The clone comprised 886 base pairs and encoded a part of murine VEGF-B.

The isolated cDNA sequence will hybridize with the mammalian genomic DNA, e.g. either murine or human, which contains the VEGF-B gene. In addition to the coding sequence, the genomic DNA will contain one or more promoter sequence(s) which give and direct expression of VEGF-B in one or more specific tissues. Thus the coding sequence of VEGF-B may be linked to an endothelial specific promoter which is specific to a certain type or types of tissue.

The nucleotide sequence is translated in two different reading frames into two different amino acid sequences. There is a stop codon (TGA) within the coding sequence at base pairs 309-311. Thus, VEGF-B comes in several splicing variants. The 5' end of the cloned cDNA sequence encodes an 102 amino acid long protein with significant homology to the N-terminal domains of VEGF, PlGF and PDGF A and B. In particular, a number of cysteine residues are perfectly conserved within this group of proteins. In addition to the nucleotide sequence (SEQ ID NO:1), FIG. 1 further depicts the deduced amino acid sequence (SEQ ID NO:2) of this first protein.

Translation of the C-terminal end of the cDNA (base pairs 308-475) in a different reading frame results in a protein which is highly homologous to the C-terminal part of VEGF.sub.165, VEGF.sub.189 and VEGF.sub.206. FIG. 2 again shows the nucleotide sequence (SEQ ID NO:1) of FIG. 1, but this time includes the deduced amino acid sequence (SEQ ID NO:3) of the second protein, which is encoded in the second reading frame and is 54 amino acids long. It thus appears that the VEGF-B gene encodes different proteins using alternative splicing of the primary transcript. The last part of the clone, encoding the second peptide might be expressed as a functional protein in other spliced variants of VEGF-B.

The aforedescribed proteins may exist in combined association with an additional N-terminal sequence of approximately five (5) to ten (10) amino acids, as well as a further leader sequence of approximately twenty-one (21) to twenty-eight (28) amino acids. Inasmuch such combined amino acid sequences exhibit the property of promoting the proliferation of endothelial cells and the DNA sequences which code for such combined peptide sequences will hybridize under stringent conditions with the DNA sequence (SEQ ID NO:1) of FIGS. 1 and 2, such amino acid sequences and the DNA which codes for them are expressly contemplated to be within the scope of the present invention.

EXAMPLE 2

Cloning of full length cDNA's for mouse VEGF-B.

Using the approximately 0.9 kb cDNA insert of the previously identified cDNA clone of Example 1 as a probe, an adult mouse heart lambda ZAP-II cDNA library obtained from Stratagene Inc., of La Jolla, Calif. was screened using standard techniques. The library was titrated and plated as recommended and filters were prepared. Following prehybridization at 42.degree. C. in 50 % formamide, 5.times. SSPE, 5.times. Denharts solution, 1 % SDS and 100 ug of salmon sperm DNA/ml, the filters were hybridized at the same temperature and in the same solution containing the denatured radiolabelled probe using 10.sup.6 cpm/ml of hybridization solution. The probe was labelled using a random priming kit (Amersham). After 16 hours the filters were washed in 2.times. SSC containing 0.5 % SDS for 2.times.30 mins at 52.degree. C. The filters were exposed overnight using intensifying screens at -70.degree. C. Positive clones were rescreened two times until all plaques on a plate were positive. The inserts were subcloned into the plasmid pBluescript SK+ by in vivo excision as recommended by the supplier.

Several clones were mapped by restriction enzyme analysis and were found to fall into two distinct groups characterized by the length of a Spe1/BamH1 restriction fragment. The first of these groups comprised three of the restriction mapped clones which each had a 240 bp Spe1/BamH1 restriction fragment. The other group comprised a clone which had a 320 bp Spe1/BamH1 fragment.

The three clones which exhibited the 240 bp Spe1/BamH1 restriction fragment were fully or partially sequenced, and the characteristics of the clones are summarized as follows:

Nucleotide sequence analyses revealed that two of the cDNA clones were substantially identical, although they differed in length, and one has a mutation. One of the clones was full length and contained an open reading frame encoding 188 amino acid residues in which the first 21 amino acids are a clevable signal sequence. The other of the two substantially identical clones terminated at the G of the start initiation codon. It could be inferred by sequence analysis of additional clones that the sequence preceeding the G reads ACCAT. Both of the clones were found to have the same coding region nucleotide sequence, which is depicted in FIG. 3 (SEQ ID NO:4). The deduced amino acid sequence of the open reading frame of the coding region of both of these two cDNA clones is shown in FIG. 4 (SEQ ID NO:5). The resulting protein encoded by this sequence is referred to hereinafter as VEGF-B.sub.166. In each of the protein names used herein, the subscript number refers to the number of amino acids in the mature protein without the signal sequence.

As would be expected, a comparison of the amino acid sequence encoded by these two clones with the partial amino acid sequence deduced from cDNA clone of Example 1 showed a striking similarity. However, the two open reading frames in the clone of Example 1, each of which encoded an amino acid sequence homologous to a different portion of VEGF, are both present in the same reading frame in each of these two clones according to Example 2. The frame shift in the clone of Example 1 is caused by an insertion of two extra adenine units which displace the C-terminal part of the clone of Example 1 out of frame. The reason for this is not presently understood, but may be due to a cloning artifact.

The coding part of the third clone had a nucleotide sequence identical to those of the preceding two clones except for a 21 bp insertion. FIG. 5 shows the nucleotide sequence of this third clone (SEQ ID NO:6). To facilitate identification, the 21 extra bases are underlined in the Figure. This insertion gives rise to 7 additional amino acid residues in the mature protein. Thus the resulting protein encoded by this longer cDNA is termed VEGF-B.sub.173. The amino acid sequence of the protein encoded by the cDNA of FIG. 5 is depicted in FIG. 6 (SEQ ID NO:7). The seven additional amino acids also are underlined in the figure for ease of identification. The additional amino acids are inserted into the sequence in a splice site, and sequencing of mouse genomic DNA clones indicates that these additional amino acids are the result of true alternative splicing. Furthermore, based on what is known about the receptor binding site locations of PDGF, the insertion occurs in a position in the protein which is probably part of a receptor binding site. The insertion is thus likely to affect receptor binding and could be of functional importance in influencing antagonist and/or different receptor specificity.

The major portion of the clone of the other group which exhibited a 320 bp Spe1/BamH1 fragment has been found to be identical to the first two clones which exhibited the 240 bp Spe1/BamH1 fragment. The difference is due to the presence of an insertion in the C-terminal part of the sequence, which is clearly a result of alternative splicing.

EXAMPLE 3

Hybrid cDNA clone.

As previously pointed out this original cDNA clone of Example 1 was not full length and may contain an artifact. However, if the extreme 5' nucleotide sequence of the clones which encode VEGF-B.sub.166 and/or VEGF-B.sub.173 is added, the open reading frame encodes a protein of 133 amino acids, yielding a mature protein which is 112 amino acids long and hence is named VEGF-B.sub.112. The hybrid cDNA sequence encoding VEGF-B.sub.112 is shown in FIG. 7, and the amino acid sequence of the corresponding protein is illustrated in FIG. 8.

FIG. 9 shows an alignment for comparison purposes of the amino acid sequences of Platelet Derived Growth Factor A (PDGF-A) (SEQ ID NO:12), Platelet Derived Growth Factor B (PDGF-B) (SEQ ID NO:13), Placenta Growth Factor (PlGF) (SEQ ID NO:14), Vascular Endothelial Growth Factor (VEGF.sub.165) (SEQ ID NO:15) and the novel 166 amino acid variant of Vascular Endothelial Growth Factor B of the present invention (VEGF-B.sub.166) (SEQ ID NO:5), which demonstrates the conserved structure of the growth factors belonging to this family of growth factors. As can be seen from this figure, the homologous relationship of the sequences is apparent, and VEGF-B is a structural homolog of the other growth factors of this group. The boxes in FIG. 9 indicate conserved cysteine residues in the respective protein amino acid sequences. It can be seen that the first eight residues are shared by all members of this family of growth factors, and it is thus evident that all cysteins in the amino terminal part (i.e. the PDGF-like domain) of the proteins are invariant. Furthermore, all the eight of the cysteins in the carboxy terminal part are of VEGF and VEGF-B are shared by both growth factors.

EXAMPLE 4

Cloning of human VEGF-B cDNA.

10.sup.6 .lambda.-clones of human fibrosarcoma cDNA library HT1080 in .lambda.gt11 (Clontech) were screened with the 0.9 kb insert of the mouse VEGF-B clone pcif 2 according to standard procedures. Among several positive clones, one, termed H.1 was analyzed more carefully and its nucleotide sequence was determined. Based on this sequence two oligonucleotides were designed that would amplify the whole coding region of putative cDNA corresponding to mouse VEGF-B.sub.166 form.

5'-CACCATGAGCCCTCTGCTCC-3' (forward) (SEQ ID NO:16) 5'-GCCATGTGTCACCTTCGCAG-3' (reverse) (SEQ ID NO:17) These oligonucleotides were used to amplify by PCR the whole coding region of human VEGF-B corresponding to mouse VEGF-B.sub.166 from oligo-dT primed human erythroleukemia cell cDNA. The amplified product was cloned into the pCR-vector of TA cloning kit (Invitrogen) and sequenced using standard techniques. The nucleotide sequence of the human VEGF-B cDNA clone is shown in FIG. 10 (SEQ ID NO:10), and the deduced amino acid sequence of human VEGF-B.sub.166 is shown in FIG. 11 (SEQ ID NO:11).

The amino acid sequences of mouse and human VEGF-B.sub.166 were aligned as shown in FIG. 12. The putative clevage site for the signal peptidase is indicated by the arrow. Excluding the signal sequences, the mouse and human VEGF-B.sub.166 amino acid sequences are highly homologous with only 20 replacements out the 166 residues. The replacements are clustered in the N-terminus, in two regions around amino acids 60 and 145. All cysteine residues in both proteins of are invariant. It is notable that the region between residues 66 and 128 is identical apart from one evolutionarily conserved replacements (Q105R). This is of importance since the receptor binding domains are found within this portion of the protein (compared to PDGF structure). From this it can be concluded that it is likely that mouse and human VEGF-B will exhibit cross-reactive binding on the receptor level and thus display identical or similar biological activities. The arrow shows the putative clevage site for the signal peptidase. Vertical bars show identical residues, while stars show amino acid residues which differ between mouse and human VEGF-B.sub.166.

VEGF-B is synthesized normally in the endoplasmic reticulum of the source cell for subsequent export. Recombinant VEGF-B may be produced by inserting a DNA sequence encoding the VEGF-B protein together with a suitable operatively linked promoter and control sequences into a suitable vector, such as the well known plasmid pBR322 or a derivative thereof, transforming or transfecting a suitable host cell, such as E. coli or a Cos cell, with the resulting vector or other systems well known in the art, screening the resulting transformants or transfectants for VEGF-B expression, and then culturing cell lines or bacterial cell strains which are positive for the expression of VEGF-B. Either a eukaryotic vector or a prokaryotic vector may be used, depending on the type of cell which is to be transfected or transformed therewith.

VEGF-B can be used as a growth factor for populations of endothelial cells in vitro. VEGF-B may be used to promote desirable angiogenesis, i.e. the formation of new blood vessels and capillaries. For example, it may be useful in promoting the development of the corpus luteum and endometrium as an aid to initiating and/or maintaining pregnancy. Administration of VEGF-B may also be useful in supporting embryogenesis, as well as somatic growth and vascular development and differentiation. Topical application of VEGF-B to wounds may be useful in promoting wound healing, and oral administration of VEGF-B may be useful to accelerate the healing of gastric and/or duodenal ulcers.

VEGF-B may exert proliferative effects on mesodermal cells either directly or via improvements in the blood supply.

Tumor assays for VEGF-B may be useful as indicators of metastatic risk. Assays of VEGF-B in body fluids or the tumor itself by histochemistry may be useful as a tumor prognostic factor. Furthermore, because tumor growth requires angiogenesis, administration of VEGF-B may also be useful in promoting tumor growth in laboratory animals in order to test anti-tumorigenic drugs. VEGF-B may also be useful to increase the microvascularity of hypoxic areas of tumors and make them more sensitive to radiation, radiation sensitizing drugs, etc.

The angiogenic action of VEGF-B may be useful in treating ischemic conditions. VEGF-B or agonists could be used to stimulate the development of collateral circulation in cases of arterial and/or venous obstruction, e.g. myocardial infarcts, ischaemic limbs, deep venous thrombisis, and/or postpartum vascular problems.

A VEGF-B/VEGF-B receptor system may be used as an assay system to detect small molecules as agonists/antagonists for development as new drugs. Examples of small molecules which could be detected include, but are not limited to, organic chemicals, peptides, and RNA molecules.

Pharmaceutical compositions may be produced by admixing a pharmaceutically effective amount of VEGF-B protein with one or more suitable carriers or adjuvants such as water, mineral oil, polyethylene glycol, starch, talcum, lactose, thickeners, stabilizers, suspending agents, etc. Such compositions may be in the form of solutions, suspensions, tablets, capsules, creams, salves, ointments, or other conventional forms.

VEGF-B protein also can be used to produce antibodies. Such antibodies may be produced using conventional antibody production techniques. For example, specific monoclonal antibodies may be produced via immunization of fusion proteins obtained by recombinant DNA expression. Labelled monoclonal antibodies, in particular, should be useful in screening for conditions associated with abnormal levels of VEGF-B in the body. For example, assays of VEGF-B levels in blood or urine may be useful as a tumor marker. These monoclonal antibodies to VEGF-B also may be useful in inhibiting angiogenesis associated with high levels of VEGF-B in the body, e.g. in rapidly proliferating, angiogenesis-dependent tumors in mammals, and thereby may retard the growth of such tumors. Treatment may be effected, e.g., by twice weekly intraperitoneal injection of 10 to 500 .mu.g, preferably 50-100 .mu.g of monoclonal antibody. For the therapy of humans, chiaserization or humanization of such monoclonal antibodies is to be preferred.

VEGF-B antagonists such as antibodies may be useful to inhibit new blood vessels in diabetic retinopathy, psoriasis, arthopathies and/or vascular tumors such as haemangiomas.

The foregoing description and examples have been set forth merely to illustrate the invention and are not intended to be limiting. Since modifications of the disclosed embodiments incorporating the spirit and substance of the invention may occur to persons skilled in the art, the invention should be construed to include everything within the scope of the appended claims and equivalents thereof.

__________________________________________________________________________SEQUENCE LISTING(1) GENERAL INFORMATION:(iii) NUMBER OF SEQUENCES: 17(2) INFORMATION FOR SEQ ID NO:1:(i) SEQUENCE CHARACTERISTICS:(A) LENGTH: 886 base pairs(B) TYPE: nucleic acid(C) STRANDEDNESS: single(D) TOPOLOGY: linear(ii) MOLECULE TYPE: cDNA(iii) HYPOTHETICAL: NO(vi) ORIGINAL SOURCE:(F) TISSUE TYPE: mouse embryo(vii) IMMEDIATE SOURCE:(B) CLONE: pcif2(xi) SEQUENCE DESCRIPTION: SEQ ID NO:1:CGGGACGCCCAGTGGTGCCATGGATAGACGTTTATGCACGTGCCACATGCCAGCCCAGGG60AGGTGGTGGTGCCTCTGAGCATGGAACTCATGGGCAATGTGGTCAAACAACTAGTGCCCA120GCTGTGTGACTGTGCAGCGCTGTGGTGGCTGCTGCCCTGACGATGGCCTGGAATGTGTGC180CCACTGGGCAACACCAAGTCCGAATGCAGATCCTCATGATCCAGTACCCGAGCAGTCAGC240TGGGGGAGATGTCCCTGGAAGAACACAGCCAATGTGAATGCAGACCAAAAAAAAAAAGGA300GAGTGCTGTGAAGCCAGACAGCCCCAGGATCCTCTGCCCGCCTTGCACCCAGCGCCGTCA360ACGCCCTGACCCCCGGACCTGCCGCTGCCGCTGCAGACGCCGCCGCTTCCTCCATTGCCA420AGGGCGGGGCTTAGAGCTCAACCCAGACACCTGTAGGTGCCGGAAGCCGCGAAAGTGACA480AGCTGCTTTCCAGACTCCACGGGCCCGGCTGCTTTTATGGCCCTGCTTCACAGGGACGAA540GAGTGGAGCACAGGCAAACCTCCTCAGTCTGGGAGGTCACTGCCCCAGGACCTGGACCTT600TTAGAGAGCTCTCTCGCCATCTTTTATCTCCCAGAGCTGCCATCTAACAATTGTCAAGGA660ACCTCATGTCTCACCTCAGGGGCCAGGGTACTCTCTCACTTAACCACCCTGGTCAAGTGA720GCATCTTCTGGCTGGCTGTCTCCCCTCACTATGAAAACCCCAAACTTCTACCAATAACGG780GATTTGGGTTCTGTTATGATAACTGTGACACACACACACACTCACACTCTGATAAAAGAG840AACTCTGATAAAAGAGATGGAAGACACTAAAAAAAAAAAAAAAAAA886(2) INFORMATION FOR SEQ ID NO:2:(i) SEQUENCE CHARACTERISTICS:(A) LENGTH: 102 amino acids(B) TYPE: amino acid(C) STRANDEDNESS: single(D) TOPOLOGY: linear(ii) MOLECULE TYPE: protein(iii) HYPOTHETICAL: NO(vi) ORIGINAL SOURCE:(F) TISSUE TYPE: mouse embryo(xi) SEQUENCE DESCRIPTION: SEQ ID NO:2:GlyArgProValValProTrpIleAspValTyrAlaArgAlaThrCys151015GlnProArgGluValValValProLeuSerMetGluLeuMetGlyAsn202530ValValLysGlnLeuValProSerCysValThrValGlnArgCysGly354045GlyCysCysProAspAspGlyLeuGluCysValProThrGlyGlnHis505560GlnValArgMetGlnIleLeuMetIleGlnTyrProSerSerGlnLeu65707580GlyGluMetSerLeuGluGluHisSerGlnCysGluCysArgProLys859095LysLysArgArgValLeu100(2) INFORMATION FOR SEQ ID NO:3:(i) SEQUENCE CHARACTERISTICS:(A) LENGTH: 55 amino acids(B) TYPE: amino acid(C) STRANDEDNESS: single(D) TOPOLOGY: linear(ii) MOLECULE TYPE: protein(iii) HYPOTHETICAL: NO(vi) ORIGINAL SOURCE:(F) TISSUE TYPE: mouse embryo(xi) SEQUENCE DESCRIPTION: SEQ ID NO:3:LysProAspSerProArgIleLeuCysProProCysThrGlnArgArg151015GlnArgProAspProArgThrCysArgCysArgCysArgArgArgArg202530PheLeuHisCysGlnGlyArgGlyLeuGluLeuAsnProAspThrCys354045ArgCysArgLysProArgLys5055(2) INFORMATION FOR SEQ ID NO:4:(i) SEQUENCE CHARACTERISTICS:(A) LENGTH: 565 base pairs(B) TYPE: nucleic acid(C) STRANDEDNESS: single(D) TOPOLOGY: linear(ii) MOLECULE TYPE: cDNA(iii) HYPOTHETICAL: NO(vi) ORIGINAL SOURCE:(F) TISSUE TYPE: adult mouse heart(xi) SEQUENCE DESCRIPTION: SEQ ID NO:4:GAGCCCCCTGCTCCGTCGCCTGCTGCTTGTTGCACTGCTGCAGCTGGCTCGCACCCAGGC60CCCTGTGTCCCAGTTTGATGGCCCCAGCCACCAGAAGAAAGTGGTGCCATGGATAGACGT120TTATGCACGTGCCACATGCCAGCCCAGGGAGGTGGTGGTGCCTCTGAGCATGGAACTCAT180GGGCAATGTGGTCAAACAACTAGTGCCCAGCTGTGTGACTGTGCAGCGCTGTGGTGGCTG240CTGCCCTGACGATGGCCTGGAATGTGTGCCCACTGGGCAACACCAAGTCCGAATGCAGAT300CCTCATGATCCAGTACCCGAGCAGTCAGCTGGGGGAGATGTCCCTGGAAGAACACAGCCA360ATGTGAATGCAGACCAAAAAAAAAGGAGAGTGCTGTGAAGCCAGACAGCCCCAGGATCCT420CTGCCCGCCTTGCACCCAGCGCCGTCAACGCCCTGACCCCCGGACCTGCCGCTGCCGCTG480CAGACGCCGCCGCTTCCTCCATTGCCAAGGGCGGGGCTTAGAGCTCAACCCAGACACCTG540TAGGTGCCGGAAGCCGCGAAAGTGA565(2) INFORMATION FOR SEQ ID NO:5:(i) SEQUENCE CHARACTERISTICS:(A) LENGTH: 188 amino acids(B) TYPE: amino acid(C) STRANDEDNESS: single(D) TOPOLOGY: linear(ii) MOLECULE TYPE: protein(iii) HYPOTHETICAL: NO(vi) ORIGINAL SOURCE:(F) TISSUE TYPE: adult mouse heart(xi) SEQUENCE DESCRIPTION: SEQ ID NO:5:MetSerProLeuLeuArgArgLeuLeuLeuValAlaLeuLeuGlnLeu151015AlaArgThrGlnAlaProValSerGlnPheAspGlyProSerHisGln202530LysLysValValProTrpIleAspValTyrAlaArgAlaThrCysGln354045ProArgGluValValValProLeuSerMetGluLeuMetGlyAsnVal505560ValLysGlnLeuValProSerCysValThrValGlnArgCysGlyGly65707580CysCysProAspAspGlyLeuGluCysValProThrGlyGlnHisGln859095ValArgMetGlnIleLeuMetIleGlnTyrProSerSerGlnLeuGly100105110GluMetSerLeuGluGluHisSerGlnCysGluCysArgProLysLys115120125LysGluSerAlaValLysProAspSerProArgIleLeuCysProPro130135140CysThrGlnArgArgGlnArgProAspProArgThrCysArgCysArg145150155160CysArgArgArgArgPheLeuHisCysGlnGlyArgGlyLeuGluLeu165170175AsnProAspThrCysArgCysArgLysProArgLys180185(2) INFORMATION FOR SEQ ID NO:6:(i) SEQUENCE CHARACTERISTICS:(A) LENGTH: 591 base pairs(B) TYPE: nucleic acid(C) STRANDEDNESS: single(D) TOPOLOGY: linear(ii) MOLECULE TYPE: cDNA(iii) HYPOTHETICAL: NO(vi) ORIGINAL SOURCE:(F) TISSUE TYPE: adult mouse heart(xi) SEQUENCE DESCRIPTION: SEQ ID NO:6:ACCATGAGCCCCCTGCTCCGTCGCCTGCTGCTTGTTGCACTGCTGCAGCTGGCTCGCACC60CAGGCCCCTGTGTCCCAGTTTGATGGCCCCAGCCACCAGAAGAAAGTGGTGCCATGGATA120GACGTTTATGCACGTGCCACATGCCAGCCCAGGGAGGTGGTGGTGCCTCTGAGCATGGAA180CTCATGGGCAATGTGGTCAAACAACTAGTGCCCAGCTGTGTGACTGTGCAGCGCTGTGGT240GGCTGCTGCCCTGACGATGGCCTGGAATGTGTGCCCACTGGGCAACACCAAGTCCGAATG300CAGGTACCAGGGCCTATGGGTCAGATCCTCATGATCCAGTACCCGAGCAGTCAGCTGGGG360GAGATGTCCCTGGAAGAACACAGCCAATGTGAATGCAGACCAAAAAAAAAGGAGAGTGCT420GTGAAGCCAGACAGCCCCAGGATCCTCTGCCCGCCTTGCACCCAGCGCCGTCAACGCCCT480GACCCCCGGACCTGCCGCTGCCGCTGCAGACGCCGCCGCTTCCTCCATTGCCAAGGGCGG540GGCTTAGAGCTCAACCCAGACACCTGTAGGTGCCGGAAGCCGCGAAAGTGA591(2) INFORMATION FOR SEQ ID NO:7:(i) SEQUENCE CHARACTERISTICS:(A) LENGTH: 195 amino acids(B) TYPE: amino acid(C) STRANDEDNESS: single(D) TOPOLOGY: linear(ii) MOLECULE TYPE: protein(iii) HYPOTHETICAL: NO(vi) ORIGINAL SOURCE:(F) TISSUE TYPE: adult mouse heart(xi) SEQUENCE DESCRIPTION: SEQ ID NO:7:MetSerProLeuLeuArgArgLeuLeuLeuValAlaLeuLeuGlnLeu151015AlaArgThrGlnAlaProValSerGlnPheAspGlyProSerHisGln202530LysLysValValProTrpIleAspValTyrAlaArgAlaThrCysGln354045ProArgGluValValValProLeuSerMetGluLeuMetGlyAsnVal505560ValLysGlnLeuValProSerCysValThrValGlnArgCysGlyGly65707580CysCysProAspAspGlyLeuGluCysValProThrGlyGlnHisGln859095ValArgMetGlnValProGlyProMetGlyGlnIleLeuMetIleGln100105110TyrProSerSerGlnLeuGlyGluMetSerLeuGluGluHisSerGln115120125CysGluCysArgProLysLysLysGluSerAlaValLysProAspSer130135140ProArgIleLeuCysProProCysThrGlnArgArgGlnArgProAsp145150155160ProArgThrCysArgCysArgCysArgArgArgArgPheLeuHisCys165170175GlnGlyArgGlyLeuGluLeuAsnProAspThrCysArgCysArgLys180185190ProArgLys195(2) INFORMATION FOR SEQ ID NO:8:(i) SEQUENCE CHARACTERISTICS:(A) LENGTH: 405 base pairs(B) TYPE: nucleic acid(C) STRANDEDNESS: single(D) TOPOLOGY: linear(ii) MOLECULE TYPE: cDNA(xi) SEQUENCE DESCRIPTION: SEQ ID NO:8:ACCATGAGCCCCCTGCTCCGTCGCCTGCTGCTTGTTGCACTGCTGCAGCTGGCTCGCACC60CAGGCCCCTGTGTCCCAGTTTGATGGCCCCAGCCACCAGAAGAAAGTGGTGCCATGGATA120GACGTTTATGCACGTGCCACATGCCAGCCCAGGGAGGTGGTGGTGCCTCTGAGCATGGAA180CTCATGGGCAATGTGGTCAAACAACTAGTGCCCAGCTGTGTGACTGTGCAGCGCTGTGGT240GGCTGCTGCCCTGACGATGGCCTGGAATGTGTGCCCACTGGGCAACACCAAGTCCGAATG300CAGATCCTCATGATCCAGTACCCGAGCAGTCAGCTGGGGGAGATGTCCCTGGAAGAACAC360AGCCAATGTGAATGCAGACCAAAAAAAAAAAGGAGAGTGCTGTGA405(2) INFORMATION FOR SEQ ID NO:9:(i) SEQUENCE CHARACTERISTICS:(A) LENGTH: 133 amino acids(B) TYPE: amino acid(C) STRANDEDNESS: single(D) TOPOLOGY: linear(ii) MOLECULE TYPE: protein(xi) SEQUENCE DESCRIPTION: SEQ ID NO:9:MetSerProLeuLeuArgArgLeuLeuLeuValAlaLeuLeuGlnLeu151015AlaArgThrGlnAlaProValSerGlnPheAspGlyProSerHisGln202530LysLysValValProTrpIleAspValTyrAlaArgAlaThrCysGln354045ProArgGluValValValProLeuSerMetGluLeuMetGlyAsnVal505560ValLysGlnLeuValProSerCysValThrValGlnArgCysGlyGly65707580CysCysProAspAspGlyLeuGluCysValProThrGlyGlnHisGln859095ValArgMetGlnIleLeuMetIleGlnTyrProSerSerGlnLeuGly100105110GluMetSerLeuGluGluHisSerGlnCysGluCysArgProLysLys115120125LysArgArgValLeu130(2) INFORMATION FOR SEQ ID NO:10:(i) SEQUENCE CHARACTERISTICS:(A) LENGTH: 570 base pairs(B) TYPE: nucleic acid(C) STRANDEDNESS: single(D) TOPOLOGY: linear(ii) MOLECULE TYPE: cDNA(iii) HYPOTHETICAL: NO(vi) ORIGINAL SOURCE:(F) TISSUE TYPE: human fibrosarcoma(xi) SEQUENCE DESCRIPTION: SEQ ID NO:10:ACCATGAGCCCTCTGCTCCGCCGCCTGCTGCTCGCCGCACTCCTGCAGCTGGCCCCCGCC60CAGGCCCCTGTCTCCCAGCCTGATGCCCCTGGCCACCAGAGGAAAGTGGTGTCATGGATA120GATGTGTATACTCGCGCTACCTGCCAGCCCCGGGAGGTGGTGGTGCCCTTGACTGTGGAG180CTCATGGGCACCGTGGCCAAACAGCTGGTGCCCAGCTGCGTGACTGTGCAGCGCTGTGGT240GGCTGCTGCCCTGACGATGGCCTGGAGTGTGTGCCCACTGGGCAGCACCAAGTCCGGATG300CAGATCCTCATGATCCGGTACCCGAGCAGTCAGCTGGGGGAGATGTCCCTGGAAGAACAC360AGCCAGTGTGAATGCAGACCTAAAAAAAAGGACAGTGCTGTGAAGCCAGACAGCCCCAGG420CCCCTCTGCCCACGCTGCACCCAGCACCACCAGCGCCCTGACCCCCGGACCTGCCGCTGC480CGCTGCCGACGCCGCAGCTTCCTCCGTTGCCAAGGGCGGGGCTTAGAGCTCAACCCAGAC540ACCTGCAGGTGCCGGAAGCTGCGAAGGTGA570(2) INFORMATION FOR SEQ ID NO:11:(i) SEQUENCE CHARACTERISTICS:(A) LENGTH: 188 amino acids(B) TYPE: amino acid(C) STRANDEDNESS: single(D) TOPOLOGY: linear(ii) MOLECULE TYPE: protein(iii) HYPOTHETICAL: NO(vi) ORIGINAL SOURCE:(F) TISSUE TYPE: human fibrosarcoma(xi) SEQUENCE DESCRIPTION: SEQ ID NO:11:MetSerProLeuLeuArgArgLeuLeuLeuAlaAlaLeuLeuGlnLeu151015AlaProAlaGlnAlaProValSerGlnProAspAlaProGlyHisGln202530ArgLysValValSerTrpIleAspValTyrThrArgAlaThrCysGln354045ProArgGluValValValProLeuThrValGluLeuMetGlyThrVal505560AlaLysGlnLeuValProSerCysValThrValGlnArgCysGlyGly65707580CysCysProAspAspGlyLeuGluCysValProThrGlyGlnHisGln859095ValArgMetGlnIleLeuMetIleArgTyrProSerSerGlnLeuGly100105110GluMetSerLeuGluGluHisSerGlnCysGluCysArgProLysLys115120125LysAspSerAlaValLysProAspSerProArgProLeuCysProArg130135140CysThrGlnHisHisGlnArgProAspProArgThrCysArgCysArg145150155160CysArgArgArgSerPheLeuArgCysGlnGlyArgGlyLeuGluLeu165170175AsnProAspThrCysArgCysArgLysLeuArgArg180185(2) INFORMATION FOR SEQ ID NO:12:(i) SEQUENCE CHARACTERISTICS:(A) LENGTH: 196 amino acids(B) TYPE: amino acid(C) STRANDEDNESS: single(D) TOPOLOGY: linear(ii) MOLECULE TYPE: protein(xi) SEQUENCE DESCRIPTION: SEQ ID NO:12:MetArgThrTrpAlaCysLeuLeuLeuLeuGlyCysGlyTyrLeuAla151015HisAlaLeuAlaGluGluAlaGluIleProArgGluLeuIleGluArg202530LeuAlaArgSerGlnIleHisSerIleArgAspLeuGlnArgLeuLeu354045GluIleAspSerValGlyAlaGluAspAlaLeuGluThrSerLeuArg505560AlaHisGlySerHisAlaIleAsnHisValProGluLysArgProVal65707580ProIleArgArgLysArgSerIleGluGluAlaIleProAlaValCys859095LysThrArgThrValIleTyrGluIleProArgSerGlnValAspPro100105110ThrSerAlaAsnPheLeuIleTrpProProCysValGluValLysArg115120125CysThrGlyCysCysAsnThrSerSerValLysCysGlnProSerArg130135140ValHisHisArgSerValLysValAlaLysValGluTyrValArgLys145150155160LysProLysLeuLysGluValGlnValArgLeuGluGluHisLeuGlu165170175CysAlaCysAlaThrSerAsnLeuAsnProAspHisArgGluGluGlu180185190ThrAspValArg195(2) INFORMATION FOR SEQ ID NO:13:(i) SEQUENCE CHARACTERISTICS:(A) LENGTH: 241 amino acids(B) TYPE: amino acid(C) STRANDEDNESS: single(D) TOPOLOGY: linear(ii) MOLECULE TYPE: protein(xi) SEQUENCE DESCRIPTION: SEQ ID NO:13:MetAsnArgCysTrpAlaLeuPheLeuProLeuCysCysTyrLeuArg151015LeuValSerAlaGluGlyAspProIleProGluGluLeuTyrGluMet202530LeuSerAspHisSerIleArgSerPheAspAspLeuGlnArgLeuLeu354045HisArgAspSerValAspGluAspGlyAlaGluLeuAspLeuAsnMet505560ThrArgAlaHisSerGlyValGluLeuGluSerSerSerArgGlyArg65707580ArgSerLeuGlySerLeuAlaAlaAlaGluProAlaValIleAlaGlu859095CysLysThrArgThrGluValPheGlnIleSerArgAsnLeuIleAsp100105110ArgThrAsnAlaAsnPheLeuValTrpProProCysValGluValGln115120125ArgCysSerGlyCysCysAsnAsnArgAsnValGlnCysArgAlaSer130135140GlnValGlnMetArgProValGlnValArgLysIleGluIleValArg145150155160LysLysProIlePheLysLysAlaThrValThrLeuGluAspHisLeu165170175AlaCysLysCysGluThrIleValThrProArgProValThrArgSer180185190ProGlyThrSerArgGluGlnArgAlaLysThrProGlnAlaArgVal195200205ThrIleArgThrValArgIleArgArgProProLysGlyLysHisArg210215220LysPheLysHisThrHisAspLysAlaAlaLeuLysGluThrLeuGly225230235240Ala(2) INFORMATION FOR SEQ ID NO:14:(i) SEQUENCE CHARACTERISTICS:(A) LENGTH: 149 amino acids(B) TYPE: amino acid(C) STRANDEDNESS: single(D) TOPOLOGY: linear(ii) MOLECULE TYPE: protein(xi) SEQUENCE DESCRIPTION: SEQ ID NO:14:MetProValMetArgLeuPheProCysPheLeuGlnLeuLeuAlaGly151015LeuAlaLeuProAlaValProProGlnGlnTrpAlaLeuSerAlaGly202530AsnGlySerSerGluValGluValValProPheGlnGluValTrpGly354045ArgSerTyrCysArgAlaLeuGluArgLeuValAspValValSerGlu505560TyrProSerGluValGluHisMetPheSerProSerCysValSerLeu65707580LeuArgCysThrGlyCysCysGlyAspGluAsnLeuHisCysValPro859095ValGluThrAlaAsnValThrMetGlnLeuLeuLysIleArgSerGly100105110AspArgProSerTyrValGluLeuThrPheSerGlnHisValArgCys115120125GluCysArgProLeuArgGluLysMetLysProGluArgCysGlyAsp130135140AlaValProArgArg145(2) INFORMATION FOR SEQ ID NO:15:(i) SEQUENCE CHARACTERISTICS:(A) LENGTH: 189 amino acids(B) TYPE: amino acid(C) STRANDEDNESS: single(D) TOPOLOGY: linear(ii) MOLECULE TYPE: protein(xi) SEQUENCE DESCRIPTION: SEQ ID NO:15:MetAsnPheLeuLeuSerTrpValHisTrpThrLeuAlaLeuLeuLeu151015TyrLeuHisHisAlaLysTrpSerGlnAlaAlaProThrThrGluGly202530GluGlnLysSerHisGluValIleLysPheAspValTyrGlnArgSer354045TyrCysArgProIleGluThrLeuValAspIlePheGlnGluTyrPro505560AspGluIleGluTyrIlePheLysProSerCysValProLeuMetArg65707580CysAlaGlyCysCysAsnAspGluAlaLeuGluCysValProThrSer859095GluSerAsnIleThrMetGlnIleMetArgIleLysProHisGlnSer100105110GlnHisIleGluArgMetSerPheLeuGlnHisSerArgCysGluCys115120125ArgProLysLysAspArgThrLysProGluAsnHisCysGluProCys130135140SerGluArgArgLysHisLeuPheValGlnAspProGlnThrCysLys145150155160CysSerCysLysAsnThrAspSerArgCysLysAlaArgGlnLeuGlu165170175LeuAsnGluArgThrCysArgCysAspLysProArgArg180185(2) INFORMATION FOR SEQ ID NO:16:(i) SEQUENCE CHARACTERISTICS:(A) LENGTH: 20 base pairs(B) TYPE: nucleic acid(C) STRANDEDNESS: single(D) TOPOLOGY: linear(ii) MOLECULE TYPE: cDNA(xi) SEQUENCE DESCRIPTION: SEQ ID NO:16:CACCATGAGCCCTCTGCTCC20(2) INFORMATION FOR SEQ ID NO:17:(i) SEQUENCE CHARACTERISTICS:(A) LENGTH: 20 base pairs(B) TYPE: nucleic acid(C) STRANDEDNESS: single(D) TOPOLOGY: linear(ii) MOLECULE TYPE: cDNA(xi) SEQUENCE DESCRIPTION: SEQ ID NO:17:GCCATGTGTCACCTTCGCAG20__________________________________________________________________________

Claims

1. An isolated protein having the property of promoting proliferation of endothelial cells or mesodermal cells, said isolated protein comprising a sequence of amino acids selected from the group consisting of the amino acid sequence of FIG. 1 (SEQ ID NO:2), the amino acid sequence of FIG. 2 (SEQ ID NO:3), the amino acid sequence of FIG. 4 (SEQ ID NO:5), the amino acid sequence of FIG. 6 (SEQ ID NO:7), the amino acid sequence of FIG. 8 (SEQ ID NO:9), and the amino acid sequence of FIG. 11 (SEQ ID NO:11).

2. An isolated protein according to claim 1, wherein said protein comprises the amino acid sequence of FIG. 1 (SEQ ID NO:2).

3. An isolated protein according to claim 1, wherein said isolated protein comprises the amino acid sequence of FIG. 2 (SEQ ID NO:3).

4. An isolated protein according to claim 1, wherein said isolated protein comprises the amino acid sequence of FIG. 4 (SEQ ID NO:5).

5. An isolated protein according to claim 1, wherein said isolated protein comprises the amino acid sequence of FIG. 6 (SEQ ID NO:7).

6. An isolated protein according to claim 1, wherein said isolated protein comprises the amino acid sequence of FIG. 8 (SEQ ID NO:9).

7. An isolated protein according to claim 1, wherein said isolated protein comprises the amino acid sequence of FIG. 11 (SEQ ID NO:11).

8. An isolated protein according to claim 1, wherein said isolated protein is a mammalian protein.

9. An isolated protein according to claim 8, wherein said mammalian protein is a murine protein.

10. An isolated protein according to claim 8, wherein said mammalian protein is a human protein.

11. An isolated protein according to claim 1, wherein said isolated protein promotes proliferation of vascular endothelial cells.

12. An isolated protein produced by expression of a DNA selected from the group consisting of the DNA of FIGS. 1 and 2 (SEQ ID NO:1), the DNA of FIG. 3 (SEQ ID NO:4), the DNA of FIG. 5 (SEQ ID NO:6), the DNA of FIG. 7 (SEQ ID NO:8), the DNA of FIG. 10 (SEQ ID NO:10), and DNA which hybridizes under stringent conditions with at least one of the foregoing DNA sequences.

13. A pharmaceutical composition comprising an effective endothelial or mesodermal cell proliferation promoting amount of an isolated protein according to claim 1, and at least one pharmaceutical carrier or diluent.